Social Media Is Fueling Enthusiasm for New Weight Loss Drugs. Are Regulators Watching?
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren鈥檛 FDA-approved for that use.
FDA
161 - 180 of 472 Results
-
The Confusing Fate of the Abortion Pill
Episode 293The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA鈥檚 approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join 杨贵妃传媒視頻 Health News chief Washington correspondent Julie Rovner to discuss these issues and more.
-
Doctors’ Lesson for Drug Industry: Abortion Wars Are Dangerous to Ignore
The American Medical Association ducked the abortion issue for years and now sees its members鈥 professional opinions second-guessed by lawmakers and judges. PhRMA is following the same playbook.
By Julie Rovner -
FDA Evaluates 鈥楽afety Concerns鈥 Over Dental Devices Featured in KHN-CBS Investigation
A KHN and CBS News investigation found that a dental appliance called the AGGA has been used by more than 10,000 patients, and multiple lawsuits allege it has caused grievous harm to patients.
A Judicial Body Blow to the ACA
Episode 291A federal judge in Texas has dealt a big setback to the Affordable Care Act. The same judge who tried in 2018 to declare the entire ACA unconstitutional has now ruled that the law鈥檚 main provisions for preventive care are unconstitutional and, therefore, unenforceable nationwide. Also this week, North Carolina became the 40th state to expand Medicaid under the ACA. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sandhya Raman of CQ Roll Call join KHN chief Washington correspondent Julie Rovner to discuss these issues and more.
-
Judge Signals He Could Rule to Halt Sales of Common Abortion Pill
A U.S. District Court case is being widely followed because the judge鈥檚 decision could overturn the FDA鈥檚 approval of mifepristone two decades ago. With abortion rights polling well even in red states, anti-abortion activists are increasingly turning to the courts to achieve their aims.
By Sarah Varney -
FDA Looks Into Dental Device After KHN-CBS News Investigation of Patient Harm
The FDA鈥檚 interest in the AGGA dental device follows a KHN-CBS News investigation, according to a former agency official.
-
Despite Pharma Claims, Illicit Drug Shipments to US Aren鈥檛 Full of Opioids. It鈥檚 Generic Viagra.
The FDA has long blocked the importation of cheap medicine, agreeing with pharmaceutical manufacturers that it opens the door to opioids. The agency鈥檚 own data shows that rarely happens.
March Medicaid Madness
Episode 287President Joe Biden and Republicans in Congress spent last month sparring over whether to shield Medicare and Social Security from budget cuts 鈥 leading some to wonder if Medicaid was on the table instead. Biden and Democrats say no, but some Republicans seem eager to trim federal spending on the health program for Americans with low incomes. And ready or not, artificial intelligence is coming to medical care. Benefits, as well as unintended consequences, are likely. Alice Miranda Ollstein of Politico, Rachel Cohrs of STAT News, and Lauren Weber of The Washington Post join KHN鈥檚 chief Washington correspondent, Julie Rovner, to discuss these issues and more.
-
One Texas Judge Will Decide Fate of Abortion Pill Used by Millions of American Women
鈥淲hat happens in Texas doesn't stay in Texas,鈥 warns an abortion rights advocate bracing for a district judge鈥檚 ruling on whether the abortion pill mifepristone was properly authorized by the FDA. His decision could force the medication off the U.S. market.
By Sarah Varney -
A Bitter Battle Over the 鈥極rphan Drug鈥 Program Leaves Patients鈥 Pocketbooks at Risk
Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.
A Health-Heavy State of the Union
Episode 284President Joe Biden鈥檚 2023 State of the Union address leaned heavily on health care issues. Biden took a victory lap for recent accomplishments like capping prescription drug costs for seniors on Medicare. He also urged Congress to make permanent the boosted premium subsidies under the Affordable Care Act, and he sparred with Republicans on threats to cut Social Security and Medicare. Also this week, both sides in the abortion debate are bracing for a court decision out of Texas that could, at least temporarily, make the abortion pill mifepristone illegal nationwide. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Kate Baicker of the University of Chicago about a possible middle ground in the effort to get universal health insurance coverage.
-
鈥榃e Ain鈥檛 Gonna Get It鈥: Why Bernie Sanders Says His ‘Medicare for All’ Dream Must Wait
As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of 鈥淢edicare for All鈥 maps out his strategy for negotiating with Republicans 鈥 and Big Pharma.
By Arthur Allen -
FDA Experts Are Still Puzzled Over Who Should Get Which Covid Shots and When
A single booster seems to prevent death and hospitalization in most people, but protection from the current vaccines wanes within months. FDA experts say they need to know more from the Centers for Disease Control and Prevention to decide the best long-term strategy.
By Arthur Allen Part I: The State of the Abortion Debate 50 Years After ‘Roe’
Episode 281In Part I of this special two-part episode, Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Sarah Varney of KHN join KHN chief Washington correspondent Julie Rovner to discuss how the abortion debate has evolved since the Supreme Court overturned the nationwide right to abortion in 2022, and what might be the flashpoints for 2023. Also in this episode, Rovner interviews Elizabeth Nash of the Guttmacher Institute, about changing reproductive policies in the states.
GOP House Opens With Abortion Agenda
Episode 279Leaders of the new Republican-led U.S. House kicked off their legislative agenda with two bills supported by anti-abortion groups. While neither is likely to become law, the move demonstrates how abortion will continue to be an issue in Washington. Meanwhile, as open enrollment for the Affordable Care Act nears its end in most states, the number of Americans covered by the plans hits a new high. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico, and Sarah Karlin-Smith of the Pink Sheet join KHN鈥檚 Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
States Challenge Biden to Lower Drug Prices by Allowing Imports From Canada
Colorado has joined Florida, New Hampshire, and New Mexico in seeking federal permission to import prescription drugs from Canada. President Joe Biden endorsed the approach in his 2020 campaign but has yet to approve any state plan.
-
KHN鈥檚 鈥榃hat the Health?鈥: Congress Races the Clock
Sen. Raphael Warnock鈥檚 re-election in Georgia will give Democrats a clear-cut Senate majority for the first time in nearly a decade. Meanwhile, the current Congress has only days left to tackle major unfinished business on the health agenda, including fending off scheduled pay cuts for doctors and other health providers in the Medicare program. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg News, and Sandhya Raman of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
The Business of Clinical Trials Is Booming. Private Equity Has Taken Notice.
Private equity-backed Headlands Research heralded its covid-19 vaccine trials as a chance to boost participation among diverse populations, then it shuttered multiple sites that conducted them.
-
As STDs Proliferate, Companies Rush to Market At-Home Test Kits. But Are They Reliable?
The popularity of at-home covid tests has amplified calls from public health researchers and diagnostic companies to make home testing similarly routine for sexually transmitted diseases. But FDA guidelines are lagging.
By Liz Szabo